Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease

Grueter T, Moellers FE, Tietz A, Dargvainiene J, Melzer N, Heidbreder A, Strippel C, Kraft A, Hoeftberger R, Schoeberl F, Thaler FS, Wickel J, Chung HY, Seifert F, Tschernatsch M, Nagel M, Lewerenz J, Jarius S, Wildemann BC, De Azevedo L, Heidenreich F, Heusgen R, Hofstadt-Van Oy U, Linsa A, Maass JJ, Menge T, Ringelstein M, Pedrosa DJ, Schill J, Seifert-Held T, Seitz C, Tonner S, Urbanek C, Zittel S, Markewitz R, Korporal-Kuhnke M, Schmitter T, Finke C, Brueggemann N, Bien C, Kleiter I, Gold R, Wandinger KP, Kuhlenbaeumer G, Leypoldt F, Ayzenberg I (2022)


Publication Type: Journal article

Publication year: 2022

Journal

DOI: 10.1093/brain/awac090

Abstract

In a large cohort of anti-IgLON5 disease patients, Gruter et al. reveal early inflammatory CSF changes, subacute relapses, and association of HLA-DRB1*10:01 with higher autoantibody titre, consistent with a primary autoimmune nature of the disease. Immunotherapy is effective if initiated early, prior to major neurodegeneration.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Grueter, T., Moellers, F.E., Tietz, A., Dargvainiene, J., Melzer, N., Heidbreder, A.,... Ayzenberg, I. (2022). Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease. Brain. https://doi.org/10.1093/brain/awac090

MLA:

Grueter, Thomas, et al. "Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease." Brain (2022).

BibTeX: Download